Bladder cancer treatment with targeted therapy

The cancerous cell’s everyday list of components necessary for average growth and development includes thousands of things. Naturally, as humanity kept discovering new data about cancer, medical practitioners and scientists began to think about what would happen if cancerous cells stopped getting all the necessary substances. Turned out that tumors in these conditions often stop growing, spreading, and, in some cases, even start shrinking. That’s how the targeted therapy core idea was developed. Scientists created certain drugs that block the production or admission of vital for tumor further growth and development cellular components (e. g. , proteins, fats, genes, some molecules, etc. ). Next, oncologists prescribe these medications to patients with bladder cancer (or other tumors). As a result, if therapy is successful, the primary tumor and metastatic lesions slowly start to fade away. Nowadays, dozens of bladder cancer targeted therapy medications are available D24, VEGF, the androgen receptor,  mTOR inhibitors, and much more. But, the most effective targeted therapy medication might sometimes be discovered only after a comprehensive genetic examination of the tumor cells and the patient’s genome. Mainly, this is because genetic mutations play a significant role in targeted therapy efficiency.